Spotlight Q&A: Outlook Therapeutics — Developing First Ophthalmic Formulation of Bevacizumab for FDA Approval

LaVoieHealthScience Client Spotlight Following is a Q&A with Lawrence Kenyon, President, CEO and CFO of Outlook Therapeutics (NASDAQ: OTLK), a late-stage clinical biotech company focused on developing the first FDA-approved ophthalmic formulation of bevacizumab-vikg to treat wet age-related macular degeneration (wet AMD) and other retinal diseases.  By way of background for our readers, age-related macular […]

Read More